Tasly Pharmaceutical Group Co., Ltd (600535.SS) released a profit for its full year that Increased, from the same period last year
The company's bottom line totaled RMB1.104 billion, or RMB0.74 per share. This compares with RMB955.586 million, or RMB0.64 per share, last year.
The company's revenue for the period fell 3.1% to RMB8.236 billion from RMB8.498 billion last year.
Tasly Pharmaceutical Group Co., Ltd earnings at a glance (GAAP) :
-Earnings: RMB1.104 Bln. vs. RMB955.586 Mln. last year.-EPS: RMB0.74 vs. RMB0.64 last year.-Revenue: RMB8.236 Bln vs. RMB8.498 Bln last year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.